

Lunch Presentation with Clearbridge Health Limited (CBH SP)

Date: 23 April 2019, Tuesday

Time: 12pm to 1pm

Venue: KGI Office 13AB

Company Background:

Clearbridge Health (CBH SP) is an integrated healthcare group with a focus on delivery of precision medicine. Precision medicine is an approach to disease treatment and prevention that takes into account individual variability in genes, environment and lifestyle. The global precision medicine market is forecasted to grow to US\$142bn by 2026 from US\$44bn in 2016, according to BIS Research.

Biolidics (BLD SP) is an associate company of CBH that specialises in developing cell enrichment systems, which when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Outlook and Q&A with CEO We have invited Clearbridge's CEO Mr Jeremy Yee and Biolidics' CEO Mr Ivan Law to give the outlook and strategy of their companies. It will be a small group meeting to facilitate more Q&A time with management.

Gallery:

